Human Neutralizing Monoclonal Antibody Efficiently Inhibits MERS-CoV Replication in Common Marmoset.

Middle East respiratory syndrome coronavirus (MERS-CoV) infection in humans is highly lethal, with a fatality rate of 35%. New prophylactic and therapeutic strategies to combat human infections are urgently needed. We isolated a fully human neutralizing antibody, MCA1, from a human survivor. The antibody recognizes the receptor-binding domain of MERS-CoV S glycoprotein and interferes with the interaction between viral S and the human cellular receptor human dipeptidyl peptidase 4 (DPP4). To our knowledge, this study is the first to report a human neutralizing monoclonal antibody that completely inhibits MERS-CoV replication in common marmosets. Monotherapy with MCA1 represents a potential alternative treatment for human infections with MERS-CoV worthy of evaluation in clinical settings. Ac ce pt ed M an us cr ipt 3 key words Human Monoclonal Antibody; MERS-CoV; Common Marmoset

[1]  Jerome H. Kim,et al.  A roadmap for MERS-CoV research and product development: report from a World Health Organization consultation , 2016, Nature Medicine.

[2]  D. Falzarano,et al.  SARS and MERS: recent insights into emerging coronaviruses , 2016, Nature Reviews Microbiology.

[3]  D. Dimitrov,et al.  Prophylaxis With a Middle East Respiratory Syndrome Coronavirus (MERS-CoV)–Specific Human Monoclonal Antibody Protects Rabbits From MERS-CoV Infection , 2016, The Journal of infectious diseases.

[4]  Ulas Bagci,et al.  3B11-N, a monoclonal antibody against MERS-CoV, reduces lung pathology in rhesus monkeys following intratracheal inoculation of MERS-CoV Jordan-n3/2012 , 2016, Virology.

[5]  Lu Lu,et al.  Characterization and Demonstration of the Value of a Lethal Mouse Model of Middle East Respiratory Syndrome Coronavirus Infection and Disease , 2015, Journal of Virology.

[6]  Shibo Jiang,et al.  Middle East respiratory syndrome: current status and future prospects for vaccine development , 2015, Expert opinion on biological therapy.

[7]  B. Bosch,et al.  Occupational Exposure to Dromedaries and Risk for MERS-CoV Infection, Qatar, 2013–2014 , 2015, Emerging infectious diseases.

[8]  Dae-Won Kim,et al.  Middle East Respiratory Syndrome Coronavirus Outbreak in the Republic of Korea, 2015 , 2015, Osong Public Health and Research Perspectives.

[9]  R. Baric,et al.  Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus , 2015, Proceedings of the National Academy of Sciences.

[10]  Jianmin Wang,et al.  Characterization of Two Human Monoclonal Antibodies Neutralizing Influenza A H7N9 Viruses , 2015, Journal of Virology.

[11]  D. Hui,et al.  Middle East respiratory syndrome , 2015, The Lancet.

[12]  G. Sutter,et al.  Protective Efficacy of Recombinant Modified Vaccinia Virus Ankara Delivering Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein , 2015, Journal of Virology.

[13]  Victor M Corman,et al.  Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia: a nationwide, cross-sectional, serological study , 2015, The Lancet Infectious Diseases.

[14]  Jianmin Wang,et al.  Human monoclonal antibodies targeting the haemagglutinin glycoprotein can neutralize H7N9 influenza virus , 2015, Nature Communications.

[15]  O. Pagani,et al.  Evidence for Camel-to-Human Transmission of MERS Coronavirus , 2015 .

[16]  B. Bosch,et al.  MERS Coronavirus Neutralizing Antibodies in Camels, Eastern Africa, 1983–1997 , 2014, Emerging infectious diseases.

[17]  Stephan Günther,et al.  Emergence of Zaire Ebola virus disease in Guinea. , 2014, The New England journal of medicine.

[18]  Yan Li,et al.  Bat Origins of MERS-CoV Supported by Bat Coronavirus HKU4 Usage of Human Receptor CD26 , 2014, Cell Host & Microbe.

[19]  Xinxia Peng,et al.  Infection with MERS-CoV Causes Lethal Pneumonia in the Common Marmoset , 2014, PLoS pathogens.

[20]  Martin Beer,et al.  Human Infection with MERS Coronavirus after Exposure to Infected Camels, Saudi Arabia, 2013 , 2014, Emerging infectious diseases.

[21]  D. Dimitrov,et al.  Exceptionally Potent Neutralization of Middle East Respiratory Syndrome Coronavirus by Human Monoclonal Antibodies , 2014, Journal of Virology.

[22]  K. Yuen,et al.  Potent Neutralization of MERS-CoV by Human Neutralizing Monoclonal Antibodies to the Viral Spike Glycoprotein , 2014, Science Translational Medicine.

[23]  R. Baric,et al.  Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution , 2014, Proceedings of the National Academy of Sciences.

[24]  Z. Memish,et al.  Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study , 2014, International Journal of Infectious Diseases.

[25]  Marion P G Koopmans,et al.  Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation , 2013, The Lancet Infectious Diseases.

[26]  Honglin Chen,et al.  An Animal Model of MERS Produced by Infection of Rhesus Macaques With MERS Coronavirus , 2013, The Journal of infectious diseases.

[27]  K. To,et al.  Active Replication of Middle East Respiratory Syndrome Coronavirus and Aberrant Induction of Inflammatory Cytokines and Chemokines in Human Macrophages: Implications for Pathogenesis , 2013, The Journal of infectious diseases.

[28]  Amit Kapoor,et al.  Middle East Respiratory Syndrome Coronavirus in Bats, Saudi Arabia , 2013, Emerging infectious diseases.

[29]  V. Corman,et al.  Close Relative of Human Middle East Respiratory Syndrome Coronavirus in Bat, South Africa , 2013, Emerging infectious diseases.

[30]  B. Bosch,et al.  Inhibition of Middle East Respiratory Syndrome Coronavirus Infection by Anti-CD26 Monoclonal Antibody , 2013, Journal of Virology.

[31]  Michael G. Katze,et al.  Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques , 2013, Proceedings of the National Academy of Sciences.

[32]  G. Sutter,et al.  Middle East Respiratory Syndrome Coronavirus Spike Protein Delivered by Modified Vaccinia Virus Ankara Efficiently Induces Virus-Neutralizing Antibodies , 2013, Journal of Virology.

[33]  Victor M Corman,et al.  Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study , 2013, The Lancet Infectious Diseases.

[34]  D. Cummings,et al.  Hospital outbreak of Middle East respiratory syndrome coronavirus. , 2013, The New England journal of medicine.

[35]  Linqi Zhang,et al.  Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4 , 2013, Cell Research.

[36]  A. Debnath,et al.  Identification of a Receptor-Binding Domain in the S Protein of the Novel Human Coronavirus Middle East Respiratory Syndrome Coronavirus as an Essential Target for Vaccine Development , 2013, Journal of Virology.

[37]  B. Bosch,et al.  The Receptor Binding Domain of the New Middle East Respiratory Syndrome Coronavirus Maps to a 231-Residue Region in the Spike Protein That Efficiently Elicits Neutralizing Antibodies , 2013, Journal of Virology.

[38]  Jie Dong,et al.  Human Infection with a Novel Avian-Origin Influenza A (H7N9) Virus. , 2018 .

[39]  Christian Drosten,et al.  Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC , 2013, Nature.

[40]  A. Osterhaus,et al.  Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. , 2012, The New England journal of medicine.

[41]  P. Woo,et al.  Genetic relatedness of the novel human group C betacoronavirus to Tylonycteris bat coronavirus HKU4 and Pipistrellus bat coronavirus HKU5 , 2012, Emerging Microbes & Infections.

[42]  R. Lanciotti,et al.  Genetic and Serologic Properties of Zika Virus Associated with an Epidemic, Yap State, Micronesia, 2007 , 2008, Emerging infectious diseases.

[43]  Airlie J. McCoy,et al.  Solving structures of protein complexes by molecular replacement with Phaser , 2006, Acta crystallographica. Section D, Biological crystallography.

[44]  Prasert Auewarakul,et al.  Probable person-to-person transmission of avian influenza A (H5N1). , 2005, The New England journal of medicine.

[45]  P. Chan,et al.  Use of convalescent plasma therapy in SARS patients in Hong Kong , 2004, European Journal of Clinical Microbiology and Infectious Diseases.

[46]  A. Fraire,et al.  Specific history of heterologous virus infections determines anti-viral immunity and immunopathology in the lung. , 2003, The American journal of pathology.

[47]  Christian Drosten,et al.  Characterization of a Novel Coronavirus Associated with Severe Acute Respiratory Syndrome , 2003, Science.

[48]  Z. Otwinowski,et al.  Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.